New drug shows promise for rare childhood disorder
Disease control
Completed
This study tested an experimental drug called GLM101 in 27 people with PMM2-CDG, a rare genetic condition that affects movement and development. Participants received different doses of the drug intravenously over 24 weeks. The main goal was to see if the drug improves coordinati…
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC